Tuesday, August 06, 2024 6:54:43 AM
WRONG on all accounts. Oh, Dina... You should probs ask pound the table for more advice. No, alias here. I know more projections from you. I am fully competent. I do not like deception and all the stock manipulation in the OTC. I call it as I see it! Greed and Californication, not a pretty look.
Recent KTTA News
- Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer • GlobeNewswire Inc. • 05/04/2026 11:01:00 AM
- Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) • GlobeNewswire Inc. • 04/20/2026 11:01:00 AM
- Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity • GlobeNewswire Inc. • 04/01/2026 11:01:00 AM
- Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/17/2026 12:01:00 PM
- Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines • GlobeNewswire Inc. • 01/13/2026 12:01:00 PM
- Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock • GlobeNewswire Inc. • 12/02/2025 12:00:00 PM
- Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock • GlobeNewswire Inc. • 11/28/2025 02:20:00 PM
- Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS • GlobeNewswire Inc. • 11/25/2025 12:00:00 PM
- Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data • GlobeNewswire Inc. • 11/24/2025 12:00:00 PM
- Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients • GlobeNewswire Inc. • 11/21/2025 05:35:00 PM
- Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study • GlobeNewswire Inc. • 11/20/2025 09:01:00 PM
- Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients • GlobeNewswire Inc. • 11/04/2025 12:03:00 PM
- Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients • GlobeNewswire Inc. • 09/16/2025 11:03:00 AM
- Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients • GlobeNewswire Inc. • 09/08/2025 11:01:00 AM
- Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 08/29/2025 12:39:00 PM
- Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 08/28/2025 11:02:00 AM
- Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients • GlobeNewswire Inc. • 07/31/2025 11:01:00 AM
- Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board • GlobeNewswire Inc. • 06/11/2025 11:02:00 AM
- Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 • GlobeNewswire Inc. • 06/02/2025 12:02:00 PM
